# Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects

## TL;DR

Ovarian cancer is hard to treat due to its complexity and late detection, and tumour-on-chip models may offer better ways to study and treat it.

## Contribution

This review identifies key challenges in ovarian cancer tumour-on-chip models and proposes strategies for improving their design and reliability.

## Key findings

- Current preclinical models poorly replicate the ovarian tumour microenvironment's complexity.
- Tumour-on-chip models offer a promising but underdeveloped approach for ovarian cancer research.
- Standardisation and improved design are needed to enhance the translational value of these models.

## Abstract

Ovarian cancer is one of the most lethal cancers in women, largely because it is often detected late, shows high diversity with intra tumour and inter tumour heterogeneity, and frequently becomes resistant to treatment. Current laboratory and animal models do not fully capture the complexity of ovarian tumours, making it difficult to predict how the disease develops or how patients will respond to therapies. Tumour-on-chip technology is an emerging tool that uses microfluidic devices to recreate key features of human tumours. In this review, we summarise how these systems have been applied to ovarian cancer research, highlight their advantages and limitations, and propose strategies for building more reliable and patient-relevant models. By considering future development of this technology, we aim to accelerate discoveries in ovarian cancer biology and improve prospects for personalised treatment.

Ovarian cancer is a highly lethal malignancy, characterised by late-stage diagnosis, marked inter- and intra-tumoural heterogeneity, and frequent development of chemoresistance. Existing preclinical models, including conventional two-dimensional cultures, three-dimensional spheroids, and organoids, only partially recapitulate the structural and functional complexity of the ovarian tumour microenvironment (TME). Tumour-on-chip (CoC) technology has emerged as a promising alternative, enabling the co-culture of tumour and stromal cells within a microengineered platform that incorporates relevant extracellular matrix components, biochemical gradients, and biomechanical cues under precisely controlled microfluidic conditions. This review provides a comprehensive overview of CoC technology relevant to ovarian cancer research, outlining fabrication strategies, device architectures, and TME-integration approaches. We systematically analyse published ovarian cancer-specific CoC models, revealing a surprisingly limited number of studies and a lack of standardisation across design parameters, materials, and outcome measures. Based on these findings, we identify critical technical and biological considerations to inform the rational design of next-generation CoC platforms, with the aim of improving their reproducibility, translational value, and potential for personalised medicine applications.